MedTrace Logo

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

NCT04843709 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-05-15

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

MRG004A

Administrated intravenously

Sponsors & Collaborators

  • Lepu Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Nashat Y Gabrail, MD · Gabrail Cancer Center Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2024-03-20
Completion
2024-07-26
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04843709 on ClinicalTrials.gov